drugset / Trial / NCT04572295
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to determine the recommended dose (RD) of E7090 in combination with other anticancer agents for subsequent phase studies.
Timeline
- Start
- 2020-10-09
- Primary completion
- 2026-06-18
- Completion
- 2026-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | E7090 | Small molecule | — | Oral |
| Background | Exemestane | Small molecule | 25 mg | Oral |
| Background | Fulvestrant | Small molecule | 500 mg | Intramuscular |